Floatz logo

Idarubicine

Adult Acute Myeloblastic Leukemia Without Maturation (M1)

Bruno C. MedeirosPhase 3Dormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Adult Acute Myeloblastic Leukemia Without Maturation (M1) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Northwestern University
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB
Mitoxantrone
Stanford University
Phase 2BBB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →